Latest news with #Immuneering
Business Insider
10-07-2025
- Business
- Business Insider
Mizuho Securities Keeps Their Buy Rating on Immuneering (IMRX)
In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Immuneering, with a price target of $10.00. The company's shares closed today at $4.45. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Harmony Biosciences Holdings, and Corvus Pharmaceuticals. According to TipRanks, Suvannavejh has an average return of -6.5% and a 40.79% success rate on recommended stocks. Currently, the analyst consensus on Immuneering is a Strong Buy with an average price target of $10.88. Based on Immuneering's latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.05 million. In comparison, last year the company had a GAAP net loss of $14.31 million Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMRX in relation to earlier this year. Earlier this month, Diana Hausman, a Director at IMRX bought 5,500.00 shares for a total of $19,835.00.
Business Insider
17-06-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and KalVista Pharmaceuticals (KALV)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immuneering (IMRX – Research Report) and KalVista Pharmaceuticals (KALV – Research Report) with bullish sentiments. Confident Investing Starts Here: KalVista Pharmaceuticals (KALV) In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on KalVista Pharmaceuticals, with a price target of $30.00. The company's shares closed last Monday at $13.04. According to Ku has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.9% and a 40.2% success rate. Ku covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Supernus Pharmaceuticals, and Verrica Pharmaceuticals. Currently, the analyst consensus on KalVista Pharmaceuticals is a Strong Buy with an average price target of $27.13, an 118.4% upside from current levels. In a report issued on June 13, Bank of America Securities also maintained a Buy rating on the stock with a $22.00 price target.
